Lupus

Betting on Benlysta, GSK nails down $3.6 billion HGS deal

Betting on Benlysta, GSK nails down $3.6 billion HGS deal

By

GlaxoSmithKline is buying Human Genome Sciences for $3.6 billion, giving it full ownership of Benlysta, along with albiglutide and darapladib, after months of M&A intrigue.

Email Newsletters

MM&M inVISION